Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4404759 | 0.99 | CTSB (0.41) | CTSBTACR3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3040552 | 0.80 | CTSB (0.43) | CTSBTACR3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3048826 | 0.79 | CTSB (0.41) | CTSBTACR3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3277219 | 0.71 | CTSB (0.42) | CTSBTACR3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3283641 | 0.71 | CTSB (0.44) | CTSBTACR3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4399875 | 0.71 | CTSB (0.48) | CTSBTACR3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4399866 | 0.71 | CTSB (0.48) | CTSBTACR3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3276524 | 0.71 | CTSB (0.42) | CTSBTACR3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4404757 | 0.70 | CTSB (0.49) | CTSBTACR3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4404765 | 0.70 | CTSB (0.49) | CTSBTACR3KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608590-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2009-10-27 | — | — | US | disclosed |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | MEDIVIR AB (SE) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | PRSS1, HPN, SPINT2 | CTSB 280/4885TACR3 3860/4885KDM4E 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.